Abstract:In China, the porcine reproductive and respiratory syndrome virus (PRRSV) has undergone several variations over the decades and contributed to the diversity of the clinical epidemic PRRSV strains. This has complicated the prevention and control of PRRS. In particular, the efficacy of the currently available commercial vaccines against the highly pathogenic NADC34-like strains is unclear. Therefore, the objective of this study was to evaluate the protection efficacy of three commercial PRRS modified-live virus (MLV) vaccines derived from classical PRRS VR2332 MLV and R98 MLV against challenge with a heterologous NADC34-like PRRSV strain, JS2021NADC34, which has high pathogenicity in pigs. PRRSV- and antibody-free piglets were immunized with the PRRS VR2332 MLV vaccine or either of two R98 MLV vaccines (from different manufacturers) and were challenged with the JS2021NADC34 strain 28 days after immunization. Rectal temperature, clinical symptoms, viremia and viral shedding from the nose, gross lesions in the thymus and lungs, microscopic lesions and viral distribution in the lungs, as well as the humoral immune response and mortality rates were recorded over a 14-day post-challenge period. The results showed that PRRS VR2332 MLV had better efficacy against the JS2021NADC34 challenge than PRRS R98 MLV, with vaccinated piglets in the former group showing transient and mild symptoms, mild pathological lesions in the lungs, mild thymic atrophy, and low viral levels in sera and nasal swabs, as well as better growth performance and a 100% survival rate. In contrast, two PRRS R98 MLVs exhibited limited efficacy against the JS2021NADC34 challenge, with the piglets in two R98 groups showing obvious clinical symptoms and pathological changes in the lungs and thymus; moreover, there were two deaths caused by PRRS in two R98 groups, respectively. Despite this, the mortality rate was lower than that of the unvaccinated piglets that were challenged with JS2021NADC34. The cumulative results demonstrate that PRRS VR2332 MLV was partly effective against the highly pathogenic PRRSV NADC34-like strain based on the observations over the 14-day post-challenge period. Thus, it might be a viable option among the commercially available vaccines for control of NADC34-like virus infections in swine herds.

Aroa Deleted Bordetella Bronchiseptica Inspiring Robust Mucosal Immune Response and Provide Full Protection Against Intranasal Challenge

A Marker-Free Bordetella bronchiseptica aroA/ bscN Double Deleted Mutant Confers Protection Against Lethal Challenge

Chitosan Microspheres Containing Bordetella Bronchiseptica Antigens As Novel Vaccine Against Atrophic Rhinitis in Pigs

Immunogenicity of Recombinant Protective Antigen and Efficacy Against Intranasal Challenge with Bordetella Bronchiseptica

Phenotypic characteristics and protective efficacy of an attenuated Mycoplasma hyopneumoniae vaccine by aerosol administration

Evaluation of Immunogenicity and Protective Efficacy of Actinobacillus Pleuropneumoniae HB04C− Mutant Lacking a Drug Resistance Marker in the Pigs

An interferon inducing porcine reproductive and respiratory syndrome virus vaccine candidate elicits protection against challenge with the heterologous virulent type 2 strain VR-2385 in pigs

Characterization and immunogenicity of an apxIA mutant of Actinobacillus pleuropneumoniae.

Protective efficacy of a candidate live attenuated vaccine derived from the SD-R strain of lineage 1 porcine reproductive and respiratory syndrome virus against a lethal challenge with HP-PRRSV HuN4 in piglets

Heterologous expression of porcine reproductive and respiratory syndrome virus glycoprotein 5 in Bordetella bronchisepticaaroA mutant

Construction of a quadruple gene-deleted vaccine confers complete protective immunity against emerging PRV variant challenge in piglets

Protection against Mycoplasma hyorhinis infection in commercial pigs via immunization with inactivated vaccines prepared with homologous or heterologous strains

A Subunit Vaccine Based on P97R1, P46, P42, and P65 from Mycoplasma Hyopneumoniae Can Induce Significant Immune Response in Piglets

Co-administration of Attenuated Mycoplasma Hyopneumoniae 168 Strain with Bacterial DNA Enhances the Local and Systemic Immune Response after Intranasal Vaccination in Pigs.

Humoral immunity is the primary means of heterologous <i>Propionibacterium acnes</i> vaccination against<i> Actinobacillus </i> <i>pleuropneumoniae</i> infection in pig

A Combinatorial Vaccine Containing Inactivated Bacterin and Subunits Provides Protection Against Actinobacillus Pleuropneumoniae Infection in Mice and Pigs

The Live Attenuated Actinobacillus Pleuropneumoniae Triple-Deletion Mutant Delta Apxic Delta Apxiic Delta Apxiv-Orf1 Strain, Slw05, Immunizes Pigs Against Lethal Challenge With Haemophilus Parasuis

Construction of a Bartha-K61-like Vaccine Using the CRISPR/Cas9 Method Confers Complete Protective Immunity Against Emerging PRV Variant Challenge in Piglets

Protective evaluation of the commercialized porcine reproductive and respiratory syndrome virus vaccines in piglets challenged by NADC34-like strain

Respiratory tract protection upon challenge of pigs vaccinated with attenuated porcine reproductive and respiratory syndrome virus vaccines

Vaccination of Piglets up to 1 Week of Age with a Single-Dose Mycoplasma hyopneumoniae Vaccine Induces Protective Immunity within 2 Weeks against Virulent Challenge in the Presence of Maternally Derived Antibodies